Company intelligence / Profile preview

Ocumetics Technology

Calgary, Alberta, Canada

Ownership: Private
Development stage: Other

Overview

Ocumetics has completed biocompatibility testing and animal studies for its Ocumetics Accommodating Lens[2][4]. The company commenced first-in-human clinical trials in 2024, with the initial study involving 15 subjects comparing the Ocumetics lens to a control lens[6][8]. Laboratory testing has demonstrated accommodation capability of up to 14 diopters, allowing focus on objects as close as 3 inches from the face[4].

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Ocumetics Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocumetics Technology.

Explore the full profile